Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2019 ∙ Vardanjani, H. M. Borna, H. Ahmadi, A.

Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ Ngocho, J. S. Magoma, B. Olomi, G. A. Mahande, M. J. Msuya, S. E. de Jonge, M. I. Mmbaga, B. T.

Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review

  • Africa
  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ Adawi, M. Bragazzi, N. L. McGonagle, D. Watad, S. Mahroum, N. Damiani, G. Conic, R. Bridgewood, C. Mahagna, H. Giacomelli, L. Eggenhoffner, R. Mahamid, M. Pigatto, P. D. M. Amital, H. Watad, A.

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ Vadlamudi, N. K. Chen, A. Marra, F.

Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis

  • Adults
  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
  • Administration
  • Coverage
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ McLaughlin, J. M. Jiang, Q. Gessner, B. D. Swerdlow, D. L. Sings, H. L. Isturiz, R. E. Jodar, L.

Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis

  • Adults
  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ Fu, J. Yi, R. Jiang, Y. Xu, S. Qin, P. Liang, Z. Chen, J.

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive diseases in China: a meta-analysis

  • Western Pacific
  • China
  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2019 ∙ Chiappini, E. Petrolini, C. Sandini, E. Licari, A. Pugni, L. Mosca, F. A. Marseglia, G. L.

Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology

  • Newborn
  • Pneumococcal disease
  • Influenza
  • Hepatitis B
  • Poliomyelitis
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ Adetokunboh, O. O. Ndwandwe, D. Awotiwon, A. Uthman, O. A. Wiysonge, C. S.

Vaccination among HIV-infected, HIV-exposed uninfected and HIV-uninfected children: a systematic review and meta-analysis of evidence related to vaccine efficacy and effectiveness

  • Africa
  • Newborn
  • Children
  • Adolescents
  • Rotavirus
  • Pneumococcal disease
  • Haemophilus influenzae type B
  • Tuberculosis
  • Hepatitis B
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2019 ∙ SAGE

Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper

  • Position paper
  • Pneumococcal disease
Download:
2019 ∙ Conseil Supérieur des Maladies Infectieuses

recommendations concerning the vaccination of children born prematurely

  • Recommendation
  • Europe
  • Luxembourg
  • Children
  • Newborn
  • Risk group
  • Pneumococcal disease
  • Hepatitis B
  • Influenza
Download:
Loading...